This is a very good post. It simply emphasises the value of the partnership with Hovione. On point is that if the drug is delivered by inhalation it requires only 1% of the drug administered orally for the same effect 9on the lung. There are no side effects, except possibly to the lung as there is not enough drug to have any effect on other organs. This partnership has basically de-risked this drug and we already have proven efficacy and safety.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.336M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $442 | 4.021K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 95955 | 2 |
View Market Depth
| Last trade - 13.22pm 26/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |